1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Alzheimer’s Disease [2017]

Alzheimer’s Disease [2017]

  • October 2017
  • ID: 5214613
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

Do KOLs see a future for beta-amyloid as a target in Alzheimer’s?

Despite the inexorable attrition rate, both big pharma and small biotechs continue to invest in Alzheimer’s disease R&D. Is the amyloid hypothesis dead or could the right drug candidate, studied in an optimally designed trial, gain approval for this much sought after indication? KOLs weigh in on how trials could be optimised and what part biomarkers can play. How can we learn from past failures? What are the chances of success for Biogen/Eisai’s aducanumab and the other beta-amyloid mAbs, as well as the BACE inhibitors, in light of the chequered history of these classes? Could tau finally prove itself as a valid target? Could drugs targeting inflammatory mechanisms or serotonin receptors play a part in this narrative? Four US and seven EU KOLs offer critical insights on four marketed and 15 pipeline drugs.

Take a tour of the report now
• The table of contents >
• The key business questions answered >
• The key KOL quotes >
• See the therapies covered >
• Find out who the 7 EU & 4 US KOLs are >
• Review an extract from the report - 1 drug profile >

Top takeaways
• Clinical attrition in the AD pipeline remains remarkably high. What do KOLs attribute this to and how can these issues be overcome so that past mistakes can be learnt from and the field moved forward?
• Several high profile failures of beta-amyloid mAbs have cast a shadow over this class.How do KOLs account for this chequered history and how do they rate the chance of success for Biogen/Eisai’s aducanumab and other drugs in this class?
• BACE inhibitors in the late-stage pipeline are extremely potent in terms of impacting beta-amyloid, but their clinical value remains uncertain. What is considered the optimal patient population for these drugs, and how do KOLs rate their safety and overall chance of success?
• How do KOLs envisage that the pathophysiological heterogeneity of AD could be exploited for therapeutic gain? Could there be potential in targeting beta-amyloid, tau, inflammatory pathways or serotonergic neurotransmission, or a combination of these?
• Biomarkers have played an increasingly important role in drug development for AD in recent years. How will their use evolve to shape trial design and the treatment of AD in the future?
• Outcome measure selection will be of critical importance to the success of clinical trials going forward. How can their use be best appropriated in order to optimise outcomes in AD trials?

Quotes

“One of the reasons we haven’t had success in approving a medication in the last 15 years is probably because we have not either used the appropriate dose or state of the disease to test that specific medication.”EU Key Opinion Leader

“Clinical diagnosis will evolve in a way that helps solidify the groups that we’re including in trials and who to best treat as the drugs come to market. Biomarkers have been a huge part of the development in the past few years and that will continue.” US Key Opinion Leader

“This will be the revolution for neurodegenerative diseases. We’ll go from complex, expensive, non-generalisable, inaccessible PET imaging that is also generally focused on amyloids, to multiple biomarkers. So combination therapy will be possible or people can be enrolled in a very homogeneous trial population, geared for a drug with a specific mechanism of action.” US Key Opinion Leader

Sample of therapies covered

Marketed therapies
• Aricept (donepezil; Eisai/Pfizer)
• Exelon (rivastigmine; Novartis)
• Razadyne (galantamine; Janssen/Shire)
• Namenda/Ebixa (memantine; Merz/Allergan/Lundbeck)

Phase III therapies
• Verubecestat (MK 8931; Merck & Co.)
• Elenbecestat (E-2609; Eisai/Biogen)
• Lanabecestat (AZD3293; AstraZeneca/Eli Lilly)
• JNJ-54861911 (Janssen)
• CNP520 (Novartis/Amgen)
• Solanezumab (LY2062430; Eli Lilly)
• Gantenerumab (R1450/RG-1450; Roche)
• Crenezumab (MABT5102A/R 5490245/RG 7412; Roche)
• Aducanumab (BART/BIIB 037/NI-10; Biogen/Eisai)
• CAD106 (amilomotide; Novartis)
• Pioglitazone (Takeda)
• Azeliragon (PF-04494700/TTP-488; vTv Therapeutics)
• Intepirdine (RVT 101/742457; Axovant Sciences)
• Idalopirdine (LU-AE58054/SGS-518; Lundbeck)
• TRx0237 (LMTX; TauRx)

KOLs interviewed

KOLs from North America
• Piero G. Antuono, Professor of Neurology, Pharmacology, and Toxicology; Director of the Dementia Research Center, Medical College of Wisconsin, Milwaukee, WI, USA
• Joshua D. Grill, Associate Professor, Psychiatry & Human Behavior School of Medicine, University of California, Irvine, CA, USA
• David Sultzer, Professor, Department of Psychiatry & Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA, USA
• Anonymous US KOL, Professor of Psychiatry, Neurology, and Gerontology at a major US university and director of an AD centre

KOLs from Europe
• Harald Jürgen Hampel, Professor of Neuroscience, Sorbonne Universités, Université Pierre et Marie Curie Institut de la Mémoire et de la Maladie d’Alzheimer; and Département de Neurologie Hôpital de la Pitié-Salpêtrière, Paris, France
• Peter Johannsen, Consultant Neurologist, Copenhagen Memory Clinic, Rigshospitalet and University of Copenhagen, Denmark
• José Luis Molinuevo, Scientific Director, Barcelonabeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain
• Bruno Vellas, Professor of Medicine, Chairman, Toulouse Gerontopole, Department of Internal Medicine and Geriatrics, Toulouse University Hospital; Head of Alzheimer Disease Clinical Research Centre, University of Toulouse, France
• Bengt Winblad, Professor and Director, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Huddinge, Sweden
• Anonymous German KOL, Professor and Head, department of gerontopsychiatry at an institute for mental health
• Anonymous German KOL, Head Neurologist, interdisciplinary clinical research center for neurodegenerative diseases at a major university hospital

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Secondary Hyperparathyroidism - Pipeline Review, H1 2020

Secondary Hyperparathyroidism - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Secondary Hyperparathyroidism - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H1 2020, provides an overview ...

Toll Like Receptor 8 - Pipeline Review, H1 2020

Toll Like Receptor 8 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Toll Like Receptor 8 - Pipeline Review, H1 2020SummaryToll Like Receptor 8 (CD288 or TLR8) - Toll-like receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens ...

Aplastic Anemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Aplastic Anemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

  • $ 2000
  • January 2020

"Aplastic Anemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report offers comprehensive insights on marketed and Phase III products for Aplastic Anemia. The marketed products ...


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on